AbbVie Inc vs Chevron Corp — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Chevron Corp trades at $196.1 (market cap $382.34B). The key difference: AbbVie Inc and Chevron Corp are close in size by market cap, and Chevron Corp pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| ABBV | CVX | |
|---|---|---|
Market Cap | $438.19B | $382.34B |
Sector | Health | Energy |
52-Week High | $263.58 | $211.14 |
52-Week Low | $197.38 | $146.72 |
Enterprise Value | $502.45B | $410.88B |
Dividend Yield | 2.79% | 3.65% |
Volume | — | 9,807,834 |
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Chevron (CVX) trades at $196.66, up 5.41% today, reflecting strong momentum amid high oil prices. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $214.25. Revenue declined to $184.43B in 2025, but net income margin held at 9.87%, with robust cash flow from operations of $33.94B. Recent news highlights strategic investments in Argentina and Greece, leveraging geopolitical tensions to boost production prospects.
Outlook is positive with oil price tailwinds and operational efficiency, but risks include volatile energy markets and debt increases. The stock offers a solid dividend yield and growth potential, supported by analyst bullishness, though investors should monitor execution on new projects and macroeconomic shifts affecting energy demand.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →